Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol provided greater increases in lung function compared to once-daily fluticasone furoate/vilanterol in patients with poorly controlled asthma.
FEV1 increased in patients with aspirin-tolerant asthma while on standard asthma treatment but declined in patients with aspirin-exacerbated respiratory disease.
Researchers evaluated the efficacy of dupilumab for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease.
Children with asthma and atopic dermatitis experience worse sleep and lung function outcomes compared with children with asthma alone.
Treatment with 300 mg lanadelumab every 2 weeks significantly reduced monthly hereditary angioedema attack rates compared with the 3-month historic baseline.
In a real-world setting, biologic agents offered diverse clinical benefits in patients with asthma with and without chronic rhinosinusitis.
Prenatal exposure to calcium carbonate antacids was associated with the development of food protein-induced allergic proctocolitis, a type of delayed inflammatory gut food allergy to protein, in offspring.
Although women are more likely than men to experience more severe asthma, they respond similarly to benralizumab therapy.
Exposure to several antibiotics during pregnancy may be linked to the development of atopic dermatitis in offspring within the first 24 months of life.
In patients with chronic rhinosinusitis with nasal polyps, regardless of their asthma status, omalizumab was associated with improvements in nasal polyps score, nasal congestion score, and sinonasal outcome test score.